Clinical experience of the expanded carrier screening for recessive genetic diseases in a large cohort study in Southern central China

中国中南部一项大型队列研究中,扩大隐性遗传病携带者筛查的临床经验

阅读:2

Abstract

Recessive monogenic disorders represent a significant cause of congenital malformations and disabilities in pediatric populations. The present study aims to provide the first comprehensive assessment of clinical experience with expanded carrier screening (ECS) panels in a large cohort from the Jiangxi province of Southern Central China. An ECS panel encompassing 147 genes associated with 155 genetic disorders was initially performed on 5,104 pre-gestational/prenatal females using next-generation sequencing. Following the identification of autosomal recessive conditions in female partners, sequential genetic testing was offered to 1,351 male partners, which included either the same ECS panel or other appropriate genetic tests. Comprehensive reproductive counseling was provided to all the identified at-risk couples (ARCs). Overall, 6,308 participants accepted ECS for 155 conditions (Female: 5,104, Male: 1,204) and approximately 38.43% (2,424/6,308) of them were detected as carriers for at least one of the 155 genetic conditions. The top four prevalent conditions identified in Jiangxi Province were α-thalassemia, GJB2-associated hearing loss, Krabbe disease and Wilson's disease. Among the participated cohort, 1,960 females were identified with AR variants and 1,351 male partners received sequential testing, at a recall rate of 68.93%. Among the tested couples, a total of 36 ARCs (36/1,357, 2.65%) were identified with the same AR (n = 27) or X-linked conditions (n = 9). Our study represents the first large-scale demonstration of the substantial feasibility of ECS in the Jiangxi population of Southern Central China. Based on our findings, we propose that incorporating genes with a carrier frequency threshold of 1/2,000 in the screening panel could serve as an optimal criterion. Our findings may contribute significantly to facilitating future clinical implementations of ECS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。